ADL Amdl,

AMDL to Present at American Stock Exchange's Online Investor Conference TUSTIN, Calif., June 21 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, today announced that its President and CEO, Gary Dreher, will present at the American Stock Exchange's Annual Online Healthcare and BioTech Investor Conference on Tuesday, June 22, 2004, at 10:30 a.m. Pacific, 1:30 p.m. Eastern. Shareholders and potential investors can hear the presentation live over the Internet at http://www.vcall.com/CEPage.asp?ID=88425 . A complete agenda of the AMEX IR Alliance Online Conference is available at http://www.vcallconferences.com/conferences/AMEX/0622-29- 2004/index.asp?ID=99206 . Windows Media Player software is needed to listen to the broadcast and is available free at http://microsoft.com/windowsmedia/EN/default.asp . Also, at least a 28.8Kbps connection to the Internet is needed to listen to the broadcast. AMDL is a theranostics company, meaning it is involved both in the treatment of cancer, with a unique Combination Immunogene Therapy, and in its detection, with the DR-70(R) cancer blood test kit. The Company currently is supplying information requested by the U.S. Food and Drug Administration as part of the process in seeking clearance to market the DR-70(R) test for monitoring colon cancer. The American Stock Exchange(R) (Amex(R)) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 138 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/. Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright